Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Investig Drugs. 2005 Jul;6(7):672-9.

The endocannabinoid system: a drug discovery perspective.

Author information

1
Department of Pharmacology, University of California, Irvine, CA 92697-4625, USA. piomelli@uci.edu

Abstract

The endocannabinoids are lipid messengers that engage the same cell surface receptors targeted by delta9-tetrahydrocannabinol, the active component of marijuana. They are produced by cells in the brain and other tissues and combine with two subtypes of G protein-coupled cannabinoid receptors, CB1 and CB2. Their ability to modulate a variety of pathophysiological processes, including appetite, pain and mood, provides unique opportunities for drug discovery. Three such opportunities are discussed here: reduction of body weight through blockade of CB1 receptors, alleviation of pain through activation of extracerebral cannabinoid receptors, and modulation of pain and anxiety through inhibition of endocannabinoid degradation.

PMID:
16044662
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center